Clinical trial

Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus

NCT06152042

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention BMF-219 Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2023-12-28

PhasePHASE2

Conditions

Type 1 Diabetes Mellitusverified · MONDO: type 1 diabetes mellitus

Interventions

BMF-219DRUG

Sponsors & collaborators

Biomea Fusion Inc.lead sponsor

Mapped research locations

DallasTexas, United States1 TorontoOntario, Canada1 San AntonioTexas, United States1 VancouverBritish Columbia, Canada1 ChattanoogaTennessee, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06152042 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.